These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26232187)

  • 21. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
    Sand S; Victorin K; Filipsson AF
    J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Procedures for calculating benchmark doses for health risk assessment.
    Gaylor D; Ryan L; Krewski D; Zhu Y
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s).
    Dorato MA; Engelhardt JA
    Regul Toxicol Pharmacol; 2005 Aug; 42(3):265-74. PubMed ID: 15979222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benchmark dose approaches in chemical health risk assessment in relation to number and distress of laboratory animals.
    Oberg M
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):451-4. PubMed ID: 20800084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Derivation of a bisphenol A oral reference dose (RfD) and drinking-water equivalent concentration.
    Willhite CC; Ball GL; McLellan CJ
    J Toxicol Environ Health B Crit Rev; 2008 Feb; 11(2):69-146. PubMed ID: 18188738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recognition of adverse and nonadverse effects in toxicity studies.
    Lewis RW; Billington R; Debryune E; Gamer A; Lang B; Carpanini F
    Toxicol Pathol; 2002; 30(1):66-74. PubMed ID: 11890477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A procedure for developing risk-based reference doses.
    Gaylor DW; Kodell RL
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the uncertainty factor for subchronic-to-chronic extrapolation: statistical analysis of toxicity data.
    Pieters MN; Kramer HJ; Slob W
    Regul Toxicol Pharmacol; 1998 Apr; 27(2):108-11. PubMed ID: 9671565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NTP toxicity report of reproductive dose range-finding study of Genistein (CAS No. 446-72-0) administered in feed to Sprague-Dawley rats.
    Delclos KB; Newbold R
    Toxic Rep Ser; 2007 Nov; (79):1-C2. PubMed ID: 18685712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calculation of benchmark doses for reproductive and developmental toxicity observed after exposure to isopropanol.
    Allen B; Gentry R; Shipp A; Van Landingham C
    Regul Toxicol Pharmacol; 1998 Aug; 28(1):38-44. PubMed ID: 9784431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis of toxicity studies in dogs and impact on the chronic reference dose for conventional pesticide chemicals.
    Dellarco VL; Rowland J; May B
    Crit Rev Toxicol; 2010 Jan; 40(1):16-23. PubMed ID: 20144133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of diurnal systemic dose of agrochemicals in regulatory toxicity testing--an integrated approach without additional animal use.
    Saghir SA; Bartels MJ; Rick DL; McCoy AT; Rasoulpour RJ; Ellis-Hutchings RG; Sue Marty M; Terry C; Bailey JP; Billington R; Bus JS
    Regul Toxicol Pharmacol; 2012 Jul; 63(2):321-32. PubMed ID: 22440553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health assessment of phosgene: approaches for derivation of reference concentration.
    Gift JS; McGaughy R; Singh DV; Sonawane B
    Regul Toxicol Pharmacol; 2008 Jun; 51(1):98-107. PubMed ID: 18440110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
    Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
    Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and assessment of a complete-detoxication strategy for Fuzi (lateral root of Aconitum carmichaeli) and its application in rheumatoid arthritis therapy.
    Tong P; Wu C; Wang X; Hu H; Jin H; Li C; Zhu Y; Shan L; Xiao L
    J Ethnopharmacol; 2013 Mar; 146(2):562-71. PubMed ID: 23376046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk assessment of thujone in foods and medicines containing sage and wormwood--evidence for a need of regulatory changes?
    Lachenmeier DW; Uebelacker M
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):437-43. PubMed ID: 20727933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NTP technical report on the toxicity studies of p-tert-butylcatechol (CAS No. 98-29-3) administered in feed to F344/N rats and B6C3F1 mice.
    Dunnick J
    Toxic Rep Ser; 2002 Nov; (70):5-51. PubMed ID: 12592414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A shared response model for clustered binary data in developmental toxicity studies.
    Pang Z; Kuk AY
    Biometrics; 2005 Dec; 61(4):1076-84. PubMed ID: 16401281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.